Current Overview on Hypercoagulability in COVID-19.
Am J Cardiovasc Drugs
; 20(5): 393-403, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-692666
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients. The pathogenesis is likely due to endothelial injury, immobilization, and an increase in circulating prothrombotic factors. Data on treatment are limited, although prophylactic anticoagulation is advised in all hospitalized patients. Herein, we have comprehensively reviewed the current literature available on CAC and highlight the pathogenesis, clinical features, and management of CAC.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Blood Coagulation Disorders
/
Coronavirus Infections
/
Chemoprevention
/
Thrombophilia
/
Pandemics
/
Hematologic Agents
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Am J Cardiovasc Drugs
Journal subject:
Vascular Diseases
/
Cardiology
/
Drug Therapy
Year:
2020
Document Type:
Article
Affiliation country:
S40256-020-00431-z
Similar
MEDLINE
...
LILACS
LIS